Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis. However, glucocorticoids used as treatment contribute to the morbidity and mortality of vasculitis. We determined whether avacopan (CCX168), an orally administered, selective C5a receptor inhibitor, could replace...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Am Soc Nephrol
Main Authors: Jayne, David R.W., Bruchfeld, Annette N., Harper, Lorraine, Schaier, Matthias, Venning, Michael C., Hamilton, Patrick, Burst, Volker, Grundmann, Franziska, Jadoul, Michel, Szombati, István, Tesař, Vladimír, Segelmark, Mårten, Potarca, Antonia, Schall, Thomas J., Bekker, Pirow
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Nephrology 2017
Assuntos:
Clinical Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5576933/
https://ncbi.nlm.nih.gov/pubmed/28400446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2016111179
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares